Search

everythinglearnresearchcommunity

for

Search:↓

The oils showed potential to kill certain cancer cells, especially from Dysphania ambrosioides.

Mood stabilizers can cause serious skin reactions; careful monitoring and immediate treatment are crucial.

DHT may reduce inflammation caused by certain bacteria in skin cells.

Oral isotretinoin is the most effective treatment for folliculitis decalvans.

DACC-based dressings are more effective than silver-based ones for treating chronic wounds with antimicrobial resistance.

A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.

Tirzepatide may improve hair loss by reducing insulin resistance.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Topical alpha-terthienyl with UVA may safely treat psoriasis without cancer risk.

Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.

Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.

Intralesional vitamin D3 is an effective and safe treatment for patchy alopecia areata with fewer side effects.

Compounds from turmeric and bitter show strong potential as antiviral agents against the influenza A virus.

A woman's hair loss was probably caused by the antifungal drug anidulafungin.

Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.

JAK inhibitors helped treat hair loss in two people with Down syndrome.

Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.

Tofacitinib and oral minoxidil may help treat Sisaipho alopecia areata.

Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.

Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.

Systemic agents like cyclosporine, methotrexate, and acitretin help manage psoriasis but have significant side effects.

The treatment was not recommended due to limited effectiveness and significant side effects.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.

New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.

Alefacept does not effectively treat severe alopecia areata.

Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.

Baricitinib effectively treated hair loss and inflammation in a patient with alopecia areata and lichen planopilaris.